Tideglusib (NP-12, NP031112) is a potent and irreversible small molecule glycogen synthase kinase 3 (GSK-3) inhibitor.
Clinical trials Tideglusib has been evaluated in clinical trials for:
Alzheimer's disease and progressive supranuclear palsy. Both clinical trials were discontinued in 2011 (PSP) and 2012 (Alzheimer's disease) due to lack of efficacy Congenital/juvenile-onset myotonic muscular dystrophy type I.
Research Tideglusib is or has been under investigation for multiple applications:
Tooth repair mechanisms that promotes dentine reinforcement of a sponge structure until the sponge biodegrades, leaving a solid dentine structure. In 2016, the results of animal studies were reported in which 0.14 mm holes in mouse teeth were permanently filled. Preclinical in vitro studies were carried out for neuroblastoma and ovarian cancer with significant ROS-induced apoptosis. Arrhythmogenic right ventricular cardiomyopathy as of 2025.
References



